INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION
https://doi.org/10.15825/1995-1191-2011-2-110-121
Abstract
Much attention has been placed recently in transplantation in highly HLA-sensitized patients. In attempts to remove these antibodies and enable successful renal transplantation, several approaches have been developed. Intravenous immunoglobulin (IVIG) was found to be effective in the treatment of autoimmune and inflammatory disorders (e. g. Kawasaki disease, Guillain-Barre syndrome). Recently, a beneficial effect of IVIG on the reduc- tion of anti-HLA antibodies was described. The anti-inflammatory effect of IVIG provides hopeful opportunities in antibody-mediated rejection (AMR) management. There are several protocols of IVIG administration for pre-transplant desensitization and AMR treatment: high-dose IVIG, low-dose IVIG + plasmapheresis, IVIG + plasmapheresis + rituximab. These advancements have enabled transplantation in patients previously considered untransplantable and in concert with new diagnostic techniques has resulted in new approaches to management of AMR.
About the Authors
A. I. Sushkov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
Y. G. Moysyuk
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
References
1. OPTN/SRTR Annual Report. 2009; Available from: http://optn.transplant.hrsa.gov/ar2009/default.htm.
2. Сушков А.И., Абрамов В.Ю., Мойсюк Я.Г. Роль пред- существующих и de novo анти-донорских антител в трансплантации почки // Вестник трансплантологии и искусственных органов. 2011. Т. 13, No 1. С. 84–91.
3. Хубутия М.Ш. и др. HLA-антитела и их значение при трансплантации почки // Трансплантология. 2010. No 3–4. С. 32–36.
4. Arumugam T.V. et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stro- ke by preventing complement-mediated neuronal cell death // Proc. Natl. Acad. Sci U S A. 2007. Vol. 104 (35). P. 14104–14109.
5. Aukrust P. et al. Release of cytokines, soluble cytoki- ne receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo // Blood. 1994. Vol. 84 (7). P. 2136–2143.
6. Bayry J. et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin // Blood. 2003. Vol. 101 (2). P. 758–765.
7. Billing H. et al. Successful treatment of chronic antibo- dy-mediated rejection with IVIG and rituximab in pedi- atric renal transplant recipients // Transplantation. 2008. Vol. 86 (9). P. 1214–1221.
8. Buchwald B. et al. Intravenous immunoglobulins neut- ralize blocking antibodies in Guillain-Barre syndrome // Ann Neurol. 2002. Vol. 51 (6). P. 673–680.
9. Casadei D.H. et al. A randomized and prospective study comparing treatment with high-dose intravenous immu-
10. noglobulin with monoclonal antibodies for rescue of kid- ney grafts with steroid-resistant rejection // Transplanta- tion. 2001. Vol. 71 (1). P. 53–58.
11. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile // Pharma- col Ther. 2004. Vol. 102 (3). P. 177–193.
12. Dean P.G., Gloor J.M., Stegall M.D. Conquering abso- lute contraindications to transplantation: positive-cross- match and ABO-incompatible kidney transplantation // Surgery. 2005. Vol. 137 (3). P. 269–273.
13. Ephrem A. et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobu- lin // Clin. Exp. Med. 2005. Vol. 5 (4). P. 135–140.
14. Fehr T. et al. Rituximab and intravenous immunoglo- bulin treatment of chronic antibody-mediated kidney allograft rejection // Transplantation. 2009. Vol. 87 (12). P. 1837–1841.
15. Gebel H.M., Bray R.A. Approaches for transplanting the sensitized patient: biology versus pharmacology // Neph- rol. Dial. Transplant. 2008. Vol. 23 (8). P. 2454–2457.
16. Gill V. et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin // Circulation. 2005. Vol. 112 (13). P. 2031–2039.
17. Gloor J.M. et al. Persistence of low levels of alloanti- body after desensitization in crossmatch-positive living- donor kidney transplantation // Transplantation. 2004. Vol. 78 (2). P. 221–227.
18. Jordan S.C. et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action // Transplantation. 1998. Vol. 66 (6). P. 800–805.
19. Jordan S.C. et al. Advances in diagnosing and managing antibody-mediated rejection // Pediatr. Nephrol. 2010. Vol. 25 (10). P. 2035–2045.
20. Jordan S.C. et al. Evaluation of intravenous immunoglo- bulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial // J. Am. Soc. Nephrol. 2004. Vol. 15 (12). P. 3256–3262.
21. Jordan S.C. et al. Intravenous immune globulin treat- ment inhibits crossmatch positivity and allows for suc- cessful transplantation of incompatible organs in living- donor and cadaver recipients // Transplantation. 2003. Vol. 76 (4). P. 631–636.
22. Jordan S.C. et al. Desensitization therapy with intrave- nous gammaglobulin (IVIG): applications in solid or- gan transplantation // Trans. Am. Clin. Climatol. Assoc. 2006. Vol. 117. P. 199–211.
23. Jordan S.C. et al. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience // Clin. Transpl. 2003. P. 193–198.
24. Jordan S.C. et al. Current approaches to treatment of antibody-mediated rejection // Pediatr. Transplant. 2005. Vol. 9 (3). P. 408–415.
25. Kaplan B., Schold J., Meier-Kriesche H.U. Overview of large database analysis in renal transplantation // Am. J. Transplant. 2003. Vol. 3 (9). P. 1052–1056.
26. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin // N. Engl. J. Med. 2001. Vol. 345 (10). P. 747–755.
27. Knezevic-Maramica I., Kruskall M.S. Intravenous im- mune globulins: an update for clinicians // Transfusion. 2003. Vol. 43 (10). P. 1460–1480.
28. Lefaucheur C. et al. Comparison of combination Plas- mapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection // Am. J. Transplant. 2009. Vol. 9 (5). P. 1099–1107.
29. Lefaucheur C. et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantati- on // Am. J. Transplant. 2008. Vol. 8 (2). P. 324–331.
30. Luke P.P. et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immuno- globulin (IVIG) in renal transplant recipients // Trans- plantation. 2001. Vol. 72 (3). P. 419–422.
31. Lutz H.U. et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent au- toimmune disease at the amplifying C3 convertase le- vel // Blood. 2004. Vol. 103 (2). P. 465–472.
32. Magee J.C. et al. Immunoglobulin prevents comple- ment-mediated hyperacute rejection in swine-to-primate xenotransplantation // J. Clin. Invest. 1995. Vol. 96 (5). P. 2404–2412.
33. Meier-Kriesche H.U. et al. Effect of waiting time on re- nal transplant outcome // Kidney Int. 2000. Vol. 58 (3). P. 1311–1317.
34. Montgomery R.A., Zachary A.A. Transplanting pati- ents with a positive donor-specific crossmatch: a sin- gle center’s perspective // Pediatr. Transplant. 2004. Vol. 8 (6). P. 535–542.
35. Montgomery R.A. et al. Plasmapheresis and intrave- nous immune globulin provides effective rescue thera- py for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-po- sitive recipients // Transplantation. 2000. Vol. 70 (6). P. 887–895.
36. Ott V.L., Fong D.C., Cambier J.C. Fc gamma RIIB as a potential molecular target for intravenous gamma globu- lin therapy // J. Allergy Clin. Immunol. 2001. Vol. 108 (4 Suppl.). P. S95–98.
37. Prasad N.K. et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lym- phocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway // J. Immu- nol. 1998. Vol. 161 (7). P. 3781–3790.
38. Racusen L.C. et al. Antibody-mediated rejection crite- ria – an addition to the Banff 97 classification of renal allograft rejection // Am. J. Transplant. 2003. Vol. 3 (6). P. 708–714.
39. Sacher R.A. Intravenous immunoglobulin consensus statement // J. Allergy Clin. Immunol. 2001. Vol. 108 (4 Suppl.). P. S139–S146.
40. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflamm- atory activity of IVIG mediated through the inhibitory Fc receptor // Science. 2001. Vol. 291 (5503). P. 484–486.
41. Solez K. et al. Banff 07 classification of renal allograft pathology: updates and future directions // Am. J. Trans- plant. 2008. Vol. 8 (4). P. 753–760.
42. Takei S., Arora Y.K., Walker S.M. Intravenous immuno- globulin contains specific antibodies inhibitory to activa- tion of T cells by staphylococcal toxin superantigens [see comment] // J. Clin. Invest. 1993. Vol. 91 (2). P. 602–607.
43. Terasaki P.I. Humoral theory of transplantation // Am. J. Transplant. 2003. Vol. 3 (6). P. 665–673.
44. Terasaki P.I., McClelland J.D. Microdroplet Assay of Human Serum Cytotoxins // Nature. 1964. Vol. 204. P. 998–1000.
45. Toyoda M. et al. Pooled human gammaglobulin modu- lates surface molecule expression and induces apoptosis in human B cells // Am. J. Transplant. 2003. Vol. 3 (2). P. 156–166.
46. Tyan D.B. et al. Intravenous immunoglobulin suppressi- on of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ // Transplantation. 1994. Vol. 57 (4). P. 553–562.
Review
For citations:
Sushkov A.I., Moysyuk Y.G. INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION. Russian Journal of Transplantology and Artificial Organs. 2011;13(2):110-121. (In Russ.) https://doi.org/10.15825/1995-1191-2011-2-110-121
Views:
2031
Email this article 